About Revolution Medicines, Inc. - Common Stock (RVMD)
Revolution Medicines Inc is a biotechnology company focused on developing innovative therapies to target difficult-to-treat cancers. The company is dedicated to advancing the field of precision medicine, leveraging its proprietary drug discovery platforms to explore new approaches to inhibit cancer-causing pathways. Through rigorous research and clinical trials, Revolution Medicines aims to bring forward novel treatments that not only address the complexities of tumor biology but also improve the effectiveness and safety of cancer care for patients. Their commitment to scientific excellence and collaboration positions them as a forward-thinking leader in the oncology space. Read More
The Wall Street Journal reported on Wednesday, citing people familiar with the matter, that AbbVie is in advanced talks to buy Revolution Medicines, while adding it couldn’t learn how much AbbVie is offering for the company.
As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for small-cap stocks, has notably outperformed the tech-heavy S&P 500 and the Nasdaq Composite. This early-January
As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a long period of living in the shadow of "Magnificent Seven" mega-caps, smaller domestic companies are finally
Many investors see this nuclear power company as a possible answer to the growing energy needs from artificial intelligence, and it has benefited from that.
Ten large-cap standouts—including Maplebear, Tower Semiconductor, Eli Lilly, On Holding, Albemarle, and key gold/silver miners—rallied last week on strong earnings, upbeat guidance, analyst upgrades, and expanded shareholder-return plans.
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.
Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safety data.
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines’ clinical-stage RAS(ON) inhibitors, including the multi-selective inhibitor daraxonrasib (RMC-6236), G12D-selective inhibitor zoldonrasib (RMC-9805) and G12C-selective inhibitor elironrasib (RMC-6291), in combination with Summit Therapeutics’ ivonescimab, a PD-1 / VEGF bispecific antibody.
